Rutgers is in the Vaccine Business
Rutgers is in the Vaccine Business
connect the screenshots edition
I wrote about Rutgers COVID-vaccine policy yesterday…
But here’s something a little more visual…
RWJ Barnabas has committed to a $1 billion investment over the next 20 years in facilities and services. Ostrowsky couldn’t say exactly where or how the bricks and mortar side of the deal will happen, but Rutgers Biomedical and Health Sciences Chancellor Brian Strom said the added capacity of Barnabas will have an impact on the bottom line by helping the new entity get a larger slice of grants and clinical studies.
“We can go to contract for research with pharma and NIH [National Institutes of Health] and other agencies, saying we have this huge population we can bring, a very diverse population, a major strength that New Jersey has to be able to bring to these clinical trials, [and] with that bring additional revenue,” noted Strom. (emphasis mine)
https://www.njspotlightnews.org/video/rutgers-rwj-barnabas-consummate-deal-for-large-academic-health-system/
The principal investigators of the Moderna and Johnson & Johnson COVID-19 vaccine clinical trials at Rutgers discuss how the university became a site, and their challenges and successes
In the race to develop a vaccine to battle the coronavirus, Rutgers has served as a site for Phase 3 COVID-19 clinical trials for two of the country’s pharmaceutical giants…
How did you recruit participants?
Carson: A key factor was getting permission to send emails to the Rutgers community and alumni who lived within a reasonable distance to alert them that we planned to be part of a vaccine trial. We asked them to respond after an online consent to complete a confidential survey with their medical and personal information. We also did a lot of advertising. Using all these avenues, including the health care worker study participants, we were able to identify about 6,000 people who were potentially eligible for the vaccine trial. Success in clinical research doesn’t happen by chance. Because we were trying to recruit so many people, most of our staff in the clinical research units became dedicated to this study. We were 100 percent committed to this trial, and that made the difference.
110 COVID-19 Investigators…
Those colleges are an absolute "no go".
Yep. You know this was not something that just sprung out of nowhere in 2020 to be ready to go for the big roll out that December. I’ve followed the work of Dr David Martin who been tracking these opportunistic monsters for 20 years. And that’s a good guess at just how long they been plotting this big score. One can only wonder how many in the upper levels knew that the shot was going to be a horrific one. Paul Offitt and Peter Hotez certainly knew.